Intravitreal Bevacizumab Therapy for Neovacular Age-related Macular Degeneration with Large ubmacular Hemorrhage

Purpoe To evaluate functional and anatomic effect of intravitreal bevacizumab (Avatin; Roche Pharma, Vienna, Autria) in patient with neovacular age-related macular degeneration (AMD) with large ubmacular hemorrhage. Deign Retropective, clinical tudy. Method Twenty-one eye of 19 AMD patient with choroidal neovacularization and large ubmacular hemorrhage involving the fovea compriing more than 50% of the total leion area were evaluated. All patient completed at leat four month of follow-up; 12 patient fulfilled 12 month or more of follow-up. Patient were treated with up to ix intravitreal bevacizumab injection (1 mg/0.04 ml) at a minimum of four-week interval. Change from baeline viual acuity (VA) core, retinal meaurement by optical coherence tomography (OCT), angiographic leion characteritic, and hemorrhage ize were analyzed. A afety aement wa performed at all viit. Reult Intravitreal bevacizumab injection were well tolerated in all patient. At month 4, VA wa table or improved (viual lo of 3 acuity line or fewer) in 100% and improved by at leat 3 line in 9.5%. Comparable reult were found at month 12. On average, the central foveal thickne decreaed ignificantly by 55 μm four week after the firt injection (P < .001) and by 52 μm at month 4 (P = .002). A ignificant anatomic improvement alo wa found for maximum retinal thickne, minimum retinal thickne, and foveal volume (P < .05) and wa maintained during four month of follow-up. Mean ize of hemorrhage wa ignificantly reduced from 19.7 mm2 at baeline to 2.5 mm2 at the four-month follow-up (P < .001). Concluion Intravitreal bevacizumab eem to be a promiing therapeutic option in eye with neovacular AMD and large ubmacular hemorrhage, with a tabilization in VA and anatomic improvement.